MediGene AG To Present At Baader Investment Conference Munich
Martinsried/Munich, 24 September, 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation at the Baader Investment Conference (BIC) in Munich held from 23 to 25 September.
Peter Llewellyn-Davies, Chief Financial Officer, will present at 2.15 pm (CEST) on 25 September. The presentation will be available for download on our website http://www.medigene.com/media-investors/reports-presentations.
Hosted by the Baader Bank Group, over 120 German and Austrian companies will present to numerous local and international institutional investors during the capital market conference, providing a comprehensive overview of their respective development. More information: http://www.baaderinvestmentconference.de/en/
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
Help employers find you! Check out all the jobs and post your resume.